Received Aug 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | — | — |
Extra Vaccine Administered (Trumenba); This non-serious case was reported by a physician via call center representative and described the occurrence of extra dose administered in a 18-year-old male patient who received Men B NVS (Bexsero) for prophylaxis. Previously administered products included Bexsero (1st dose received on 13-JUN-2024 under the old schedule). Concomitant products included Meningococcal vaccine B rfHbpA/fHbpB (Trumenba). On 12-MAR-2025, the patient received the 2nd dose of Bexsero. On 12-MAR-2025, an unknown time after receiving Bexsero, the patient experienced extra dose administered (Verbatim: Extra Vaccine Administered (Trumenba)). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 19-AUG-2025 The patient who received the 1st dose of Bexsero under the old schedule and received Trumenba. The patient received 2nd dose of Bexsero, which led extra dose administered. The reporter consented to follow up.; Sender's Comments: US-GSK-US2025AMR108524:same reporter different patient
TRUMENBA